抗藥性癲癇市場－全球產業規模、佔有率、趨勢、機會、預測：按治療類型、最終用戶、地區和競爭格局分類，2021-2031年

全球抗藥性癲癇市場預計將從 2025 年的 26.8 億美元大幅成長至 2031 年的 35.9 億美元，複合年成長率為 4.99%。

這種疾病的特徵是，儘管經過兩種耐受性良好且選擇合適的抗癲癇藥物的全面試驗，癲癇發作仍然持續存在。市場成長的主要促進因素包括抗藥性癲癇盛行率的不斷上升，以及對傳統藥物療法以外的治療方案的迫切臨床需求。此外，創新第三代抗癲癇藥物研發的大量投資以及神經刺激設備的進步也是推動市場擴張的重要因素。受影響人群的龐大規模顯而易見；根據癲癇基金會估計，到2025年，僅在美國就有至少一百萬人將患有無法控制的癲癇。

另一方面，市場成長的一大障礙是先進治療方法帶來的沉重經濟負擔。神經外科手術和植入式醫療設備的高昂直接醫療費用，加上開發中國家不完善的報銷體系，常常限制了患者獲得這些必要治療的機會，並阻礙了其廣泛應用。

市場促進因素

神經刺激設備的突破性技術正在從根本上改變藥物難治性癲癇的治療格局，為不適合手術切除的患者提供了至關重要的選擇。響應性神經刺激和迷走神經刺激技術的創新顯著提高了即時檢測和抑制癲癇發作的能力，有效彌合了藥物治療和高侵入性手術之間的差距。隨著臨床醫生擴大使用這些基於設備的治療方法來改善患者的生活品質，該領域的商業性化正在迅速推進。例如，NeuroPace公司於2025年11月發布的2025年第三季財報顯示，其總營收為2,740萬美元，較去年同期成長30%。這主要得益於強勁的初始植入率和不斷擴大的處方醫生群體。

另一個關鍵驅動力是具有獨特作用機制的新型療法的問世，促使市場重點從傳統的頻譜藥物轉向更個人化的精準醫療方法。能夠精準靶向特定鈉通道構型的新型藥物製劑，透過提高無發作率並滿足困難病例的複雜且未被滿足的需求，正在創造巨大的市場價值。根據SK BioPharma於2025年11月發布的2025年第三季財報，其抗癲癇藥物Xcopri在美國的銷售額達到1,722億韓元，較去年同期成長51.9%。這一成長趨勢也得益於整個產業的強勁財務表現。根據Jazz Pharmaceuticals同樣於2025年11月發布的2025年第三季財報，包括關鍵癲癇治療藥物在內的神經科學領域總銷售額達到8.274億美元，凸顯了先進癲癇治療藥物的龐大經濟規模。

市場挑戰

與先進治療方案相關的巨大經濟負擔是限制全球抗藥性癲癇市場成長的主要因素。儘管神經外科手術和植入式醫療設備的創新帶來了顯著的臨床效益，但其高昂的直接醫療成本卻成為病患獲得治療的主要障礙。這種經濟壓力在新興經濟體尤為突出，因為這些地區的醫保報銷機制往往不足以涵蓋第三代抗癲癇藥物和特殊外科手術的高昂費用。因此，治療成本與患者支付能力之間的差距不斷擴大，限制了治療的可近性，也使得市場難以將疾病的高發生率轉化為實際效益。

這種經濟差距限制了先進治療方法的商業性應用，使其主要局限於富裕地區，導致全球絕大多數患者無法獲得足夠的醫療保健。疾病負擔與經濟資源之間的巨大不平衡顯而易見。癲癇研究所報告稱，到2025年，全球5,000萬癲癇患者中，近80%將居住在中低收入國家。這些地區往往缺乏支持昂貴治療方法所需的財政資源，直接阻礙了先進治療方案在已開發國家以外的市場擴張。

市場趨勢

基因療法在罕見和難治性癲癇症候群治療領域的出現，標誌著市場格局的變革性轉變，它不再局限於單純的症狀治療，而是有望從根本上改變疾病本身。與主要調節離子通道的傳統抗癲癇藥物不同，這些精準的基因療法靶向德拉韋症候群等疾病的根本分子機制，為攜帶特定基因突變的患者帶來了新的希望。這一趨勢吸引了大量資本投資，並促進了先鋒生物技術公司與大型製藥公司之間的策略合作，鞏固了基因療法的商業性可行性。例如，Stoke Therapeutics公司於2025年8月發布的2025年第二季財報顯示，該公司透過與Biogen的合作，上半年銷售額達到1.556億美元，凸顯了這些新一代RNA治療方法可望帶來的巨大經濟價值。

同時，微創雷射間質熱療（LITT）作為一種比傳統開顱手術更安全的局部癲癇治療方法，在臨床實踐中越來越受到青睞。該技術利用磁振造影（MRI）引導的雷射消熔，以亞毫米級的精度精確破壞致癇灶，與傳統切除手術相比，顯著縮短了恢復時間並減少了手術併發症。大量臨床證據表明，LITT在實現長期癲癇控制方面療效顯著，這加速了其應用，並促使其被納入標準手術方案。 Monteris Medical公司計劃於2025年7月在《美國醫學會神經病學雜誌》（JAMA Neurology）上發表的一篇論文顯示，大規模研究表明，58.4%的受試患者在一年後達到無發作狀態（Engel分級1期），證實了該療法的臨床效用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球抗藥性癲癇市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（神經運動療法、抗癲癇藥物、苯二氮平類藥物、癲癇切除手術、特定代謝療法、特定基因療法、免疫療法）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美抗藥性癲癇市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲抗藥性癲癇市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區抗藥性癲癇市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲抗藥性癲癇市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲抗藥性癲癇市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球抗藥性癲癇市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• UCB SA
• Jazz Pharmaceuticals
• LivaNova PLC
• NeuroPace, Inc.
• Avenue Therapeutics
• Xenon Pharmaceuticals Inc.
• Marinus Pharmaceuticals
• PTC Therapeutics
• Aquestive Therapeutics
• GW Pharmaceuticals

第16章 策略建議

第17章：關於研究公司及免責聲明

The global market for drug-resistant epilepsy is projected to expand significantly, rising from USD 2.68 billion in 2025 to USD 3.59 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 4.99%. This condition is defined by the continued presence of seizures despite adequate trials of two well-tolerated and appropriately selected anti-seizure medications. Key drivers for this market's growth include the increasing prevalence of drug-resistant epilepsy and a pressing clinical need for treatment options beyond conventional pharmacological approaches. Furthermore, substantial investments in developing innovative third-generation antiepileptic drugs and advancements in neurostimulation devices are acting as significant accelerators for market expansion. The large scale of the patient population is evident, with the Epilepsy Foundation reporting that in 2025, at least 1 million individuals in the United States alone were living with uncontrolled epilepsy.

Conversely, a major hindrance to market growth is the considerable financial burden associated with advanced therapeutic options. The high direct medical costs of neurosurgical procedures and implantable devices, combined with insufficient reimbursement mechanisms in developing economies, frequently limit patient access to these crucial therapies and impede their widespread adoption.

Market Driver

Technological breakthroughs in neurostimulation devices are fundamentally transforming the treatment landscape for drug-resistant epilepsy, providing a vital option for patients who are not candidates for resective surgery. Innovations in responsive neurostimulation and vagus nerve stimulation have significantly improved the ability to detect and stop seizures in real-time, effectively bridging the gap between medication management and more invasive procedures. This segment is experiencing rapid commercial uptake as clinicians increasingly prescribe these device-based therapies to enhance patients' quality of life. For instance, NeuroPace, Inc.'s 'Third Quarter 2025 Financial Results' in November 2025 reported total revenue of $27.4 million, marking a 30 percent year-over-year increase, primarily driven by robust initial implant volumes and an expanding base of prescribers.

Another critical driver is the introduction of novel therapeutics with distinct mechanisms of action, shifting the market focus from traditional broad-spectrum agents towards a more personalized precision medicine approach. New drug formulations, such as those precisely targeting specific sodium channel configurations, are achieving higher rates of seizure freedom and generating considerable market value by addressing the complex, unmet needs of challenging cases. SK Biopharmaceuticals' 'Third Quarter 2025 Earnings Results' in November 2025 showed U.S. sales of their anti-seizure medication Xcopri soaring to KRW 172.2 billion, a 51.9 percent increase from the previous year. The overall financial robustness of the sector further supports this upward trend; Jazz Pharmaceuticals' 'Third Quarter 2025 Financial Results' in November 2025 revealed that total neuroscience revenue, encompassing key epilepsy franchises, climbed to $827.4 million, underscoring the substantial economic scale of advanced epilepsy care.

Market Challenge

The significant economic strain linked to advanced treatment options represents a primary impediment to the growth of the global drug-resistant epilepsy market. While innovations in neurosurgical interventions and implantable devices offer considerable clinical advantages, their elevated direct medical costs present a substantial barrier to patient access. This financial pressure is particularly pronounced in emerging economies, where reimbursement frameworks are frequently inadequate to cover the high prices of third-generation antiepileptic drugs or specialized surgical procedures. Consequently, the market struggles to translate the high prevalence of the condition into actual revenue, as the widening gap between treatment cost and patient affordability limits uptake.

This financial disparity restricts the commercial adoption of premium therapies predominantly to wealthier regions, leaving a large segment of the global patient population underserved. The stark imbalance between the disease burden and economic capacity is evident; the Epilepsy Research Institute reported in 2025 that nearly 80 percent of the 50 million individuals worldwide living with epilepsy resided in low- and middle-income countries. These regions often lack the necessary financial infrastructure to support expensive interventions, directly hindering the market's ability to expand advanced therapeutic solutions beyond developed nations.

Market Trends

The emergence of gene therapies for rare and intractable epilepsy syndromes signifies a transformative evolution within the market, moving beyond mere symptomatic management toward potentially modifying the disease itself. Unlike conventional anticonvulsants that primarily modulate ion channels, these precise genetic medicines target the fundamental molecular causes of conditions like Dravet syndrome, offering renewed hope for patients with specific genetic mutations. This trend is attracting considerable capital investment and fostering strategic collaborations between pioneering biotech firms and major pharmaceutical companies, thereby affirming the commercial viability of genetic interventions. For example, Stoke Therapeutics' 'Second Quarter 2025 Financial Results' in August 2025 reported revenue from its collaboration with Biogen reaching $155.6 million for the first half of the year, underscoring the substantial economic value attributed to these next-generation RNA-based treatments.

Simultaneously, there is a growing clinical preference for minimally invasive laser interstitial thermal therapy (LITT) as a safer alternative to traditional open craniotomy for focal epilepsy. This technique employs MRI-guided laser ablation to precisely destroy epileptogenic zones with sub-millimeter accuracy, leading to significantly shorter recovery times and reduced surgical complications compared to conventional resective procedures. The adoption of LITT is being accelerated by robust clinical evidence that demonstrates its effectiveness in achieving long-term seizure control, thus driving its integration into standard surgical protocols. According to Monteris Medical's announcement in July 2025 regarding a prospective publication in JAMA Neurology, a major study using the NeuroBlate(R) System for epilepsy revealed that 58.4 percent of treated patients achieved Engel 1 seizure freedom at one year, confirming the therapy's clinical utility.

Key Market Players

• UCB S.A.
• Jazz Pharmaceuticals
• LivaNova PLC
• NeuroPace, Inc.
• Avenue Therapeutics
• Xenon Pharmaceuticals Inc.
• Marinus Pharmaceuticals
• PTC Therapeutics
• Aquestive Therapeutics
• GW Pharmaceuticals

Report Scope

In this report, the Global Drug-Resistant Epilepsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug-Resistant Epilepsy Market, By Treatment Type

• Neuromodulation Therapy
• Antiseizure Medications
• Benzodiazepines
• Resective Epilepsy Surgery
• Specific Metabolic Treatment
• Specific Genetic Treatment
• Immunotherapy

Drug-Resistant Epilepsy Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Drug-Resistant Epilepsy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug-Resistant Epilepsy Market.

Available Customizations:

Global Drug-Resistant Epilepsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Drug-Resistant Epilepsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Neuromodulation Therapy, Antiseizure Medications, Benzodiazepines, Resective Epilepsy Surgery, Specific Metabolic Treatment, Specific Genetic Treatment, Immunotherapy)
  • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Drug-Resistant Epilepsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Drug-Resistant Epilepsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Drug-Resistant Epilepsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Drug-Resistant Epilepsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End User

7. Europe Drug-Resistant Epilepsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Drug-Resistant Epilepsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End User
  • 7.3.2. France Drug-Resistant Epilepsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Drug-Resistant Epilepsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Drug-Resistant Epilepsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Drug-Resistant Epilepsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By End User

8. Asia Pacific Drug-Resistant Epilepsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Drug-Resistant Epilepsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Drug-Resistant Epilepsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Drug-Resistant Epilepsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Drug-Resistant Epilepsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Drug-Resistant Epilepsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By End User

9. Middle East & Africa Drug-Resistant Epilepsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Drug-Resistant Epilepsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End User
  • 9.3.2. UAE Drug-Resistant Epilepsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End User
  • 9.3.3. South Africa Drug-Resistant Epilepsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End User

10. South America Drug-Resistant Epilepsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Drug-Resistant Epilepsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Colombia Drug-Resistant Epilepsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By End User
  • 10.3.3. Argentina Drug-Resistant Epilepsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Drug-Resistant Epilepsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. UCB S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Jazz Pharmaceuticals
• 15.3. LivaNova PLC
• 15.4. NeuroPace, Inc.
• 15.5. Avenue Therapeutics
• 15.6. Xenon Pharmaceuticals Inc.
• 15.7. Marinus Pharmaceuticals
• 15.8. PTC Therapeutics
• 15.9. Aquestive Therapeutics
• 15.10. GW Pharmaceuticals

16. Strategic Recommendations

17. About Us & Disclaimer